Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G/A BIOTRICITY INC. Filed by: Ionic Ventures, LLC

May 12, 2026 4:06 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 7 to Statement on Schedule 13G (this ''Amendment No. 7''), such shares and percentage are based on 28,436,643 shares of the common stock, par value $0.001 per share, of the issuer (the ''Common Stock'') outstanding as of February 11, 2026, as disclosed in the issuer's Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2025, filed by the issuer with the U.S. Securities and Exchange Commission (''SEC'') on February 11, 2026 (the ''Form 10-Q''). Ownership consists of (i) 532,757 shares of Common Stock held by the reporting person and (ii) an aggregate of up to 2,564,230 shares of Common Stock (the ''Conversion Shares'') issuable upon conversion of shares of Series B Convertible Preferred Stock, par value $0.001 per share, of the issuer (the ''Preferred Stock'') directly held by the reporting person, further conversions of which are subject to a 9.99% beneficial ownership limitation provision (the ''Blocker'') contained in the issuer's Amended Certificate of Designations of the Preferred Stock (the ''Certificate of Designations'').


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 7, such shares and percentage are based on 28,436,643 shares of Common Stock outstanding as of February 11, 2026, as disclosed in the Form 10-Q. Ownership consists of (i) 532,757 shares of Common Stock indirectly held by the reporting person and (ii) an aggregate of up to 2,564,230 Conversion Shares issuable upon conversion of shares of Preferred Stock indirectly held by the reporting person, further conversions of which are subject to the Blocker contained in the Certificate of Designations.


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 7, such shares and percentage are based on 28,436,643 shares of Common Stock outstanding as of February 11, 2026, as disclosed in the Form 10-Q. Ownership consists of (i) 532,757 shares of Common Stock indirectly held by the reporting person and (ii) an aggregate of up to 2,564,230 Conversion Shares issuable upon conversion of shares of Preferred Stock indirectly held by the reporting person, further conversions of which are subject to the Blocker contained in the Certificate of Designations.


SCHEDULE 13G




Comment for Type of Reporting Person: As more fully described in Item 4 of this Amendment No. 7, such shares and percentage are based on 28,436,643 shares of Common Stock outstanding as of February 11, 2026, as disclosed in the Registration Statement. Ownership consists of (i) 532,757 shares of Common Stock indirectly held by the reporting person and (ii) an aggregate of up to 2,564,230 Conversion Shares issuable upon conversion of shares of Preferred Stock indirectly held by the reporting person, further conversions of which are subject to the Blocker contained in the Certificate of Designations.


SCHEDULE 13G



Ionic Ventures, LLC
Signature:/s/ Keith Coulston
Name/Title:Keith Coulston, Manager of Ionic Management, LLC, Manager of Ionic Ventures, LLC
Date:05/12/2026
Ionic Management, LLC
Signature:/s/ Keith Coulston
Name/Title:Keith Coulston, Manager
Date:05/12/2026
Brendan O'Neil
Signature:/s/ Brendan O'Neil
Name/Title:Brendan O'Neil
Date:05/12/2026
Keith Coulston
Signature:/s/ Keith Coulston
Name/Title:Keith Coulston
Date:05/12/2026

Comments accompanying signature: LIST OF EXHIBITS Exhibit No. 1 - Joint Filing Agreement, dated August 8, 2024 (incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons with the SEC on August 8, 2024).

Categories

SEC Filings